The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
Open accessAbstract
SUMMARY Herein we report that the VEGFR/PDGFR kinase inhibitor sunitinib/SU11248 can accelerate metastatic tumor growth and decrease overall survival in mice receiving short-term therapy in various metastasis assays, including after intravenous injection of tumor cells or after removal of primary orthotopically grown tumors. Acceleration of metastasis was also observed in mice receiving sunitinib prior to intravenous implantation of tumor cells, suggesting possible “metastatic conditioning” in multiple organs. Similar findings with additional VEGF receptor tyrosine kinase inhibitors implicate a class-specific effect for such agents. Importantly, these observations of metastatic acceleration were in contrast to the demonstrable antitumor benefits obtained when the same human breast cancer cells, as well as mouse or human melanoma cells, were grown orthotopically as primary tumors and subjected to identical sunitinib treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
Kaplan, R. N., Riba, R. D., Zacharoulis, S., Bramley, A. H., Vincent, L., Costa, C., MacDonald, D. D., Jin, D. K., Shido, K., Kerns, S. A., et al. (2005) · Nature · doi:10.1038/nature04186 · Cited by 3,288
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
Pàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,339
Angiogenesis: an organizing principle for drug discovery?
Folkman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2115 · Cited by 2,246
Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621
VEGF-Induced Adult Neovascularization: Recruitment, Retention, and Role of Accessory Cells
Grunewald, M., Avraham, I., Dor, Y., Bachar-Lustig, E., Itin, A., Yung, S., Chimenti, S., Landsman, L., Abramovitch, R., & Keshet, E. (2006) · Cell · doi:10.1016/j.cell.2005.10.036 · Cited by 1,126
Rapid vascular regrowth in tumors after reversal of VEGF inhibition
Mancuso, M. R., Davis, R., Norberg, S. M., O'Brien, S., Sennino, B., Nakahara, T., Yao, V. J., Inai, T., Brooks, P., Freimark, B., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24612 · Cited by 809
Burstein, H. J., Elias, A. D., Rugo, H. S., Cobleigh, M. A., Wolff, A. C., Eisenberg, P. D., Lehman, M., Adams, B. J., Bello, C. L., DePrimo, S. E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5375 · Cited by 489
Systemic Endocrine Instigation of Indolent Tumor Growth Requires Osteopontin
McAllister, S. S., Gifford, A. M., Greiner, A. L., Kelleher, S. P., Saelzler, M. P., Ince, T. A., Reinhardt, F., Harris, L. N., Hylander, B. L., Repasky, E. A., et al. (2008) · Cell · doi:10.1016/j.cell.2008.04.045 · Cited by 431
Ebos, J. M. L., Lee, C. R., Christensen, J. G., Mutsaers, A. J., & Kerbel, R. S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708148104 · Cited by 367
Self-citationRole of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression
Shojaei, F., Singh, M., Thompson, J. D., & Ferrara, N. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712185105 · Cited by 334
Osteopontin: regulation in tumor metastasis
Wai, P. Y., & Kuo, P. C. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9104-9 · Cited by 321
Organ selectivity in metastasis: regulation by chemokines and their receptors
Ben-Baruch, A. (2008) · Clinical & Experimental Metastasis · doi:10.1007/s10585-007-9097-3 · Cited by 264
Inflammation, inflammatory cells and angiogenesis: decisions and indecisions
Noonan, D. M., De Lerma Barbaro, A., Vannini, N., Mortara, L., & Albini, A. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9108-5 · Cited by 253
Munoz, R., Man, S., Shaked, Y., Lee, C. R., Wong, J., Francia, G., & Kerbel, R. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4411 · Cited by 230
Self-citationNatori, T., Sata, M., Washida, M., Hirata, Y., Nagai, R., & Makuuchi, M. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02335-5 · Cited by 200
Christensen, J. G. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm408 · Cited by 147
Self-citationA “class action” against the microenvironment: do cancer cells cooperate in metastasis?
Bidard, F., Pierga, J., Vincent‐Salomon, A., & Poupon, M. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9103-x · Cited by 129
Sunitinib malate for the treatment of solid tumours: a review of current clinical data
Motzer, R. J., Hoosen, S., Bello, C. L., & Christensen, J. G. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.5.553 · Cited by 119
Self-citationEbos, J. M. L., Lee, C. R., Bogdanovic, E., Alami, J., Slyke, P. V., Francia, G., Xu, P., Mutsaers, A. J., Dumont, D., & Kerbel, R. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3217 · Cited by 115
Self-citationOkazaki, T., Ebihara, S., Asada, M., Kanda, A., Sasaki, H., & Yamaya, M. (2005) · International Immunology · doi:10.1093/intimm/dxh334 · Cited by 104
Enhancement by drugs of metastatic lung nodule formation after intravenous tumour cell injection
Putten, L. M. V., Kram, L. K. J., Dierendonck, H. H. C. V., et al. (1975) · International Journal of Cancer · doi:10.1002/ijc.2910150408 · Cited by 101
Johannsen, M., Flörcken, A., Bex, A., Roigas, J., Cosentino, M., Ficarra, V., Kloeters, C., Rief, M., Rogalla, P., Miller, K., et al. (2008) · European Urology · doi:10.1016/j.eururo.2008.10.021 · Cited by 97
Modulation of tumor angiogenesis by stem cell factor.
Zhang, W., Stoica, G., Tasca, S. I., Kelly, K. A., & Meininger, C. J. (2000) · PubMed · Cited by 81
Man, S., Muñoz, R., & Kerbel, R. S. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9087-6 · Cited by 46
Self-citationBeaudry, P., Nilsson, M. B., Rioth, M. J., Prox, D., Poon, D., Xu, L., Zweidler‐McKay, P. A., Ryan, A. J., Folkman, J., Ryeom, S. W., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0568 · Cited by 46
Vollmer, T. R., & Conley, F. K. (1984) · PubMed · Cited by 21
de Ruiter, J., Cramer, S. J., Lelieveld, P., et al. (1982) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(82)90047-5 · Cited by 17
Cited by
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
Tumor Metastasis: Molecular Insights and Evolving Paradigms
Valastyan, S., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.09.024 · Cited by 4,011
Integrins in cancer: biological implications and therapeutic opportunities
Desgrosellier, J. S., & Cheresh, D. A. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2748 · Cited by 3,736
Hypoxia-inducible factors in physiology and medicine
Semenza, G. L. (2012) · Cell · doi:10.1016/j.cell.2012.01.021 · Cited by 3,645
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
Metadata
- Authors
- Ebos, J. M. L., Lee, C. R., Cruz-Munoz, W., Bjarnason, G. A., Christensen, J. G., & Kerbel, R. S.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2009-03
- Volume
- 15
- Issue
- 3
- Pages
- 232-239
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W1967600348
- Cited by
- 1,709
- References
- 29
- FWCI
- 78.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.